Login to Your Account

Taiho reports positive results from phase III trial of mCRC candidate

By Catherine Makino
Contributing Writer

Wednesday, July 2, 2014

TOKYO – Japan's Taiho Oncology Inc. reported positive results from a global phase III trial of its oral combination anticancer drug TAS-102 (trifluridine and tipiracil hydrochloride) in refractory metastatic colorectal cancer (mCRC).

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription